FMP

FMP

Enter

IMPL - Impel Pharmaceuticals Inc.

Profile of Impel Pharmaceuticals Inc.(IMPL), Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development

photo-url-https://financialmodelingprep.com/image-stock/IMPL.png

Impel Pharmaceuticals Inc.

IMPL

NASDAQ

0.04 USD

-0.015 (-37.5%)

About

ceo

Mr. Leonard S. Paolillo

sector

Healthcare

industry

Biotechnology

website

https://impelpharma.com

exchange

NASDAQ

Description

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

CIK

0001445499

ISIN

US45258K1097

CUSIP

45258K109

Address

201 Elliott Avenue West

Phone

206 568 1466

Country

US

Employee

160

IPO Date

Apr 23, 2021

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep